The proteomic landscape of genotoxic stress-induced micronuclei.

DNA damage chromothripsis genotoxin mass spectrometry micronuclei mitotic errors proteomics radiation spliceosome

Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
22 Feb 2024
Historique:
received: 02 08 2023
revised: 20 12 2023
accepted: 05 02 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 29 2 2024
Statut: aheadofprint

Résumé

Micronuclei (MN) are induced by various genotoxic stressors and amass nuclear- and cytoplasmic-resident proteins, priming the cell for MN-driven signaling cascades. Here, we measured the proteome of micronuclear, cytoplasmic, and nuclear fractions from human cells exposed to a panel of six genotoxins, comprehensively profiling their MN protein landscape. We find that MN assemble a proteome distinct from both surrounding cytoplasm and parental nuclei, depleted of spliceosome and DNA damage repair components while enriched for a subset of the replisome. We show that the depletion of splicing machinery within transcriptionally active MN contributes to intra-MN DNA damage, a known precursor to chromothripsis. The presence of transcription machinery in MN is stress-dependent, causing a contextual induction of MN DNA damage through spliceosome deficiency. This dataset represents a unique resource detailing the global proteome of MN, guiding mechanistic studies of MN generation and MN-associated outcomes of genotoxic stress.

Identifiants

pubmed: 38423013
pii: S1097-2765(24)00097-2
doi: 10.1016/j.molcel.2024.02.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.D.S. has received research funding from Takeda Pharmaceuticals and BMS and consulting fees/honorarium from Takeda, Novartis, BMS, and AstraZeneca. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada.

Auteurs

Kate M MacDonald (KM)

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.

Shahbaz Khan (S)

Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C4, Canada.

Brian Lin (B)

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.

Rose Hurren (R)

Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C4, Canada.

Aaron D Schimmer (AD)

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C4, Canada.

Thomas Kislinger (T)

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C4, Canada.

Shane M Harding (SM)

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C4, Canada; Department of Radiation Oncology and Immunology, University of Toronto, Toronto, ON M5T 1P5, Canada. Electronic address: shane.harding@uhn.ca.

Classifications MeSH